A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL

This study is testing a combination of two drugs — golidocitinib (a targeted drug that blocks immune signaling) and pomalidomide (an immune-modifying drug) — for people with peripheral T-cell lymphoma (a type of immune cell cancer) that has come back or stopped responding to previous treatment. **You may be eligible if...** - You are aged 18–80 - You have been diagnosed with peripheral T-cell lymphoma (PTCL) confirmed by biopsy - Your lymphoma has relapsed (came back) or is refractory (did not respond) to at least one prior treatment - You have at least one measurable tumor on scans - Your general health/performance status is good enough to participate (ECOG 0–2) - Your blood counts and organ function meet required levels **You may NOT be eligible if...** - Your lymphoma has spread to the brain or spinal fluid - You have had another cancer in the last 5 years (except minor skin cancers) - You have previously received an allogeneic (donor) stem cell transplant - You have previously been treated with golidocitinib or pomalidomide - You are on blood thinners or anticoagulants that cannot be stopped - You require ongoing steroids or immunosuppressive drugs Talk to your doctor to see if this trial is right for you.